References
- Centers for Medicare and Medicaid Services. National Health Expenditure Projections 2018-2027 [cited 2019 Mar 14]. Available from: https://www.cms.gov/research-statistics-data-and-systems/statistics-trends-and-reports/nationalhealthexpenddata/downloads/forecastsummary.pdf
- Connecticut General Assembly [Internet]. Non-medical switching of medications; 2017 [cited 2018 Oct 5]. Available from: https://www.cga.ct.gov/2017/rpt/2017-R-0008.htm
- Nguyen E, Weeda ER, Sobieraj DM, et al. Impact of non-medical switching on clinical and economic outcomes, resource utilization and medication-taking behavior: a systematic literature review. Curr Med Res Opin. 2016;32:1281–1290.
- Pharmacopeia US [Internet]. Principles of a sound drug formulary system; 2000 [cited 2019 May 19]. Available from: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=9280
- Academy of Managed Care Pharmacy [Internet]. Formulary management; November 2009 [cited 2018 Oct 5]. Available from: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=9298
- Doshi JA, Li P, Ladage VP, et al. Impact of cost sharing on specialty drug utilization and outcomes: a review of the evidence and future directions. Am J Manag Care. 2016;2:188–197.
- Luiza VL, Chaves LA, Silva RM, et al. Pharmaceutical policies: effects of cap and co-payment on rational use of medicines. Cochrane Database Syst Rev. 2015;5:CD007017.
- Louder AM, Joshi AV, Ball AT, et al. Impact of celecoxib restrictions in medicare beneficiaries with arthritis. Am J Manag Care. 2011;17:503–512.
- Shirneshan E, Kyrychenko P, Matlin OS, et al. Impact of a transition to more restrictive drug formulary on therapy discontinuation and medication adherence. J Clin Pharm Ther. 2016;41:64–69.
- Lu CY, Ross-Degnan D, Soumerai SB, et al. Interventions designed to improve the quality and efficiency of medication use in managed care: a critical review of the literature - 2001-2007. BMC Health Serv Res. 2008;8:75.
- Wu EQ, Ben-Hamadi R, Yu AP, et al. Healthcare utilization and costs incurred by patients with major depression after being switched from escitalopram to another SSRI for non-medical reasons. J Med Econ. 2010;13:314–323.
- Philipson TJ, Mozaffari E, Maclean JR. Pharmacy cost sharing, antiplatelet therapy utilization, and health outcomes for patients with acute coronary syndrome. Am J Manag Care. 2010;16:290–297.
- Björnsdóttir US, Gizurarson S, Sabale U. Potential negative consequences of non-consented switch of inhaled medications and devices in asthma patients. Int J Clin Pract. 2013;67:904–910.
- Happe LE, Clark D, Holliday E, et al. A systematic literature review assessing the directional impact of managed care formulary restrictions on medication adherence, clinical outcomes, economic outcomes, and health care resource utilization. J Manag Care Spec Pharm. 2014;20:677–684.
- Gibofsky A, Skup M, Mittal M, et al. Effects of non-medical switching on outcomes among patients prescribed tumor necrosis factor inhibitors. Curr Med Res Opin. 2017;33:1945–1953.
- Manhattan Institute [Internet]. Older drugs, shorter lives? An examination of the health effects of the Veterans Health Administration formulary; October 2005 [cited 2018 Oct 5]. Available from: https://www.manhattan-institute.org/pdf/mpr_02.pdf
- Numan S, Faccin F. Non-medical switching from originator tumor necrosis factor inhibitors to their biosimilars: systematic review of randomized controlled trials and real-world studies. Adv Ther. 2018;35:1295–1332.
- CVS Health [Internet]. Standard formulary list of removals and updates; 2016 [cited 2018 Oct 5]. Available from: http://investors.cvshealth.com/~/media/Files/C/CVS-IR-v3/documents/02-aug-2016/2017-standard-formulary-list-of-removals-and-updates.pdf
- Dolinar R, Lavernia F, Edelman S. A guide to follow-on biologicals and biosimilars with a focus on insulin. Endocr Pract. 2018;24:195–204.
- U.S. Food and Drug Administration [Internet]. Biosimilar product regulatory review and approval; [cited 2018 Oct 5]. Available from: https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/UCM581309.pdf
- U.S. Food and Drug Administration [Internet]. FDA Purple Book: lists of licensed biological products with reference product exclusivity and biosimilarity or interchangeability evaluations; 2018 October 1 [cited 2018 Oct 5]. Available from: https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/biosimilars/ucm411418.htm
- United Health. Prescription drug list 2019. [cited 2019 Feb 7]. Available from: https://www.uhc.com/content/dam/uhcdotcom/en/Pharmacy/PDFs/100-18273-4T-Trad-1-1-19-v9-FINAL.pdf
- American Diabetes Association. Standards of medical care in diabetes – 2018. Diabetes Care. 2018;41(Suppl 1):S1–S159.
- American Association of Clinical Endocrinologists [Internet]. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on patient access to necessary and appropriate medical care; 2017 February 7 [cited 2018 Oct 5]. Available from: https://www.aace.com/files/position-statements/Patient-Access-to-Necessary-and-Appropriate-Medical-Care.pdf
- Alliance for the Adoption of Innovations in Medicine [Internet]. Nonmedical switching; 2018 [cited 2018 Oct 5]. Available from: http://www.aimedalliance.org/nonmedical-switching
- National Conference of State Legislatures [Internet]. State laws and legislation related to biologic medications and substitution of biosimilars; 2018 October 22 [cited 2019 May 19]. Available from: http://www.ncsl.org/research/health/state-laws-and-legislation-related-to-biologic-medications-and-substitution-of-biosimilars.aspx
- Global Healthy Living Foundation Creaky Joints [Internet]. Tennessee patient sentiment toward non-medical prescription drug switching by health insurance companies; 2016 [cited 2018 Oct 5]. Available from: https://creakyjoints.org/wp-content/uploads/GHLF-Tennessee_Patient_Sentiment.pdf
- Global Healthy Living Foundation Creaky Joints [Internet]. Florida patient sentiment toward non-medical prescription drug switching by health insurance companies; 2016 [cited 2018 Oct 5]. Available from: https://creakyjoints.org/wp-content/uploads/2017/01/GHLF_Florida_Patient_Sentiment_on_Drug-Switching.pdf
- Global Healthy Living Foundation [Internet]. Patient perspectives on medication switching for non-medical reasons; 2015 [cited 2018 Oct 5]. Available from: https://www.50statenetwork.org/wp-content/uploads/2015/04/GHLF-Switching-Stable-Patients-Survey_Summary.pdf
- Alliance for Safe Biologic Medicines [Internet]. ASBM advisory board members convene on physician notification; 2012 June [cited 2018 Oct 5]. Available from: https://safebiologics.org/wp-content/uploads/2012/06/Advisory-Board-Physician-Notification-final.pdf
- Wolf D, Skup M, Yang H, et al. Clinical outcomes associated with switching or discontinuation from anti-TNF inhibitors for nonmedical reasons. Clin Ther. 2017;39:849–862.e6.
- Cote BR, Petersen EA. Impact of therapeutic switching in long-term care. Am J Manag Care. 2008;14(11 Suppl):SP23–SP28.
- Grimberg A, Feudtner C, Gordon C. Consequences of brand switches during the course of pediatric growth hormone treatment. Endocr Pract. 2011;18:307–316.
- Wilkins AR, Venkat MV, Brown AS, et al. Patient Perspectives on Biosimilar Insulin. J Diabetes Sci Technol. 2014;8:23–25.
- Flores NM, Patel CA, Bookhart BK, et al. Consequences of non-medical switch among patients with type 2 diabetes. Curr Med Res Opin. 2018;34:1475–1481.
- National Institutes of Health (NIH). Financial aid for medical treatment; 2014 October 29 [cited 2019 May 19]. Available from: https://www.genome.gov/11008842/
- Tefferi A, Kantarjian H, Rajkumar SV, et al. In support of a patient-driven initiative and petition to lower the high price of cancer drugs. Mayo Clin Proc. 2015;90:996–1000.
- Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121:4439–4442.
- Lucio SD, Stevenson JG, Hoffman JM. Biosimilars: primer for the health-system pharmacist. Am J Health Syst Pharm. 2013;70:2004–2017.
- Eaddy MT, Cook CL, O’Day K, et al. How patient cost-sharing trends affect adherence and outcomes: a literature review. P T. 2012;37:45–55.
- Litton LM, Sisk FA, Akins ME. Managing drug costs: the perception of managed care pharmacy directors. Am J Manag Care. 2000;6:805–814.
- Institute for Patient Access [Internet]. Cost-motivated treatment changes: implications for non-medical switching; 2016 October [cited 2018 Oct 5]. Available from: http://allianceforpatientaccess.org/wp-content/uploads/2016/10/IfPA_Cost-Motivated-Treatment-Changes_October-2016.pdf
- Signorovitch J, Bao Y, Samuelson T, et al. Switching from adalimumab to other disease-modifying antirheumatic drugs without apparent medical reasons in rheumatoid arthritis: impact on health care service use. Annals Rheum Dis. 2013;71:717.
- Centers for Medicaid & Medicare Services [Internet]. Medicare Prescription Drug (Part D); 2017 [cited 2018 Oct 5]. Available from: https://www.cms.gov/Medicare/Appeals-and-Grievances/MedPrescriptDrugApplGriev/Downloads/Flowchart-Medicare-Part-D.pdf
- Centers for Medicaid & Medicare Services [Internet]. Medicare prescription drug appeals & grievances; exceptions; 2018 January 30 [cited 2018 Oct 5]. Available from: https://www.cms.gov/Medicare/Appeals-and-Grievances/MedPrescriptDrugApplGriev/Exceptions.html
- Alliance for the Adoption of Innovations in Medicine [Internet]. Aimed Alliance poll: principles for US health care; 2016 December 15 [cited 2018 Oct 5]. Available from: http://www.aimedalliance.org/wp-content/uploads/2016/12/Aimed-Alliance-Principles-for-U.S.-Health-Care-Poll.pdf
- Worthy SL, McClughen DC, Kulkarni S. Now or never: the urgent need for action against unfair coverage denials for quality health care. Loyola Univ Chic Law J. 2016-2017;48:1041–1097.
- Hemphil TA. The “troubles” with pharmacy benefit managers; 2017 [cited 2019 May 19]. Available from: https://object.cato.org/sites/cato.org/files/serials/files/regulation/2017/3/regulation-v40n1-5.pdf
- Kouvelis P, Xiao Y, Yang N. PBM competition in pharmaceutical supply chain: formulary design and drug pricing. Manuf Serv Oper Manag. 2015;15:511–526.
- Pharmaceutical Research and Manufacturers of America [Internet]. Follow the dollar: understanding how the pharmaceutical distribution and payment system shapes the prices of brand medicines; November 2017 [cited 2018 Oct 5]. Available from: http://phrma-docs.phrma.org/files/dmfile/Follow-the-Dollar-Report.pdf
- ASHP. Statement on the pharmacy and therapeutics committee and the formulary system; 2008 [cited 2019 May 19]. Available from: https://www.ashp.org/-/media/assets/policy-guidelines/docs/statements/pharmacy-and-therapeutics-committee-and-formulary-system.ashx
- US Dept Health and Human Sciences Office of the Assistant Secretary for Planning and Evaluation [Internet]. Cost control for prescription drug programs: pharmacy benefit manager (PBM) efforts, effects and implications; 2009 August 8 [cited 2018 Oct 5]. Available from: https://aspe.hhs.gov/cost-control-prescription-drug-programs-pharmacy-benefit-manager-pbm-efforts-effects-and-implications
- Pharmacy benefit managers could be in legislative crosshairs. 2017. Available from: https://blog.transparentrx.com/2017/01/pharmacy-benefit-managers-could-be-in.html
- The Rheumatologist [Internet]. Alliance working to rein in the power of PBMs; 2017 May 17 [cited 2018 Oct 5]. Available from: http://www.the-rheumatologist.org/article/alliance-working-rein-power-pbms/?singlepage=1&theme=print-friendly